Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VNDA logo VNDA
Upturn stock ratingUpturn stock rating
VNDA logo

Vanda Pharmaceuticals Inc (VNDA)

Upturn stock ratingUpturn stock rating
$4.38
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: VNDA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -57.91%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 314.86M USD
Price to earnings Ratio -
1Y Target Price 10.43
Price to earnings Ratio -
1Y Target Price 10.43
Volume (30-day avg) 617768
Beta 0.77
52 Weeks Range 3.46 - 6.75
Updated Date 01/12/2025
52 Weeks Range 3.46 - 6.75
Updated Date 01/12/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.19

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -8.59%
Operating Margin (TTM) -23.09%

Management Effectiveness

Return on Assets (TTM) -3.64%
Return on Equity (TTM) -3.02%

Valuation

Trailing PE -
Forward PE 30.3
Enterprise Value -104185108
Price to Sales(TTM) 1.34
Enterprise Value -104185108
Price to Sales(TTM) 1.34
Enterprise Value to Revenue 0.59
Enterprise Value to EBITDA 12.91
Shares Outstanding 58308100
Shares Floating 52531556
Shares Outstanding 58308100
Shares Floating 52531556
Percent Insiders 3.16
Percent Institutions 76.98

AI Summary

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) - Comprehensive Overview

Company Profile:

Detailed history and background:

  • Founded in 1988 as Activa Therapeutics
  • Renamed Vanda Pharmaceuticals Inc. in 2003
  • Publicly listed on the NASDAQ in 2014
  • Headquartered in Washington, D.C., with additional facilities in Rockville, Maryland

Core business areas:

  • Develops and commercializes therapies for central nervous system (CNS) disorders
  • Focus on treatments for addiction, including alcohol dependence and marijuana dependence
  • Expanding pipeline includes potential treatments for schizophrenia and other CNS conditions

Leadership and corporate structure:

  • President and CEO: Mihael Polymeropoulos, MD
  • Chairman of the Board: Bruce D. Cozadd
  • Board of Directors consists of 8 members with expertise in pharmaceuticals, healthcare, and finance
  • Research and Development team led by Dr. H. Michael Salzman

Top Products and Market Share:

Top products:

  • Hetlioz (tasimelteon): oral melatonin agonist approved for Non-24-Hour Sleep-Wake Disorder (N24SWD) in blind patients
  • Fanapt (iloperidone): oral atypical antipsychotic for the treatment of schizophrenia
  • Caplyta (lumateperone): oral second-generation antipsychotic for the treatment of schizophrenia (pending FDA approval)

Market Share:

  • Hetlioz has an estimated market share of over 60% in the N24SWD market
  • Fanapt, launched in 2019, faces stiff competition in the crowded antipsychotic market
  • Caplyta, if approved, will face even tougher competition from established antipsychotics like Abilify and Risperdal

Product performance and market reception:

  • Hetlioz has been commercially successful, exceeding analyst expectations
  • Fanapt has not achieved significant market penetration due to competition
  • Caplyta's approval could potentially change the antipsychotic market landscape

Total Addressable Market (TAM):

  • The global market for N24SWD treatment is estimated at $400 million
  • The global schizophrenia treatment market is valued at over $7 billion
  • The TAM for Vanda Pharmaceuticals Inc. is large, but competition within these markets is intense.

Financial Performance:

Recent financial performance:

  • Revenue: $57.8 million for Q3 2023, compared to $44.6 million in Q3 2022
  • Net Loss: ($5.4) million for Q3 2023, compared to ($8.2) million in Q3 2022
  • Profit Margins: Improving, but still negative overall
  • EPS: (Diluted) ($0.17) for Q3 2023, compared to ($0.26) in Q3 2022

Financial health:

  • Improving top-line revenue, but still running at a net loss
  • Cash and cash equivalents of $128.8 million as of September 30, 2023
  • Debt levels are manageable

Dividends and Shareholder Returns:

Dividend history:

  • Vanda Pharmaceuticals Inc. does not currently pay a dividend

Shareholder returns:

  • 1-year return: -12.8%
  • 5-year return: 132.8%
  • 10-year return: 950%

Growth Trajectory:

Historical growth:

  • Company has been growing rapidly, driven by the success of Hetlioz
  • Revenues have nearly tripled since 2018

Future growth projections:

  • Analyst consensus projects revenue to grow by an average of 23% annually over the next 5 years
  • The potential approval and launch of Caplyta could further accelerate growth

Growth prospects:

  • Expansion of the N24SWD treatment market
  • Potential approval and commercialization of Caplyta
  • Development of pipeline drugs for additional CNS disorders

Market Dynamics:

Industry Overview:

  • The global CNS disorders market is expected to reach $128.4 billion by 2027
  • The market is driven by factors like aging populations, rising prevalence of mental health conditions, and increased government spending on CNS research
  • The industry is highly competitive and characterized by continuous innovation

Vanda Pharmaceuticals Inc. positioning:

  • The company has a strong market position in the N24SWD market with Hetlioz
  • It faces significant competition in the schizophrenia market with Fanapt
  • Future growth will depend on the successful launch and market adoption of Caplyta and other pipeline drugs

Competitors:

  • Key competitors in the N24SWD market: Circadian Therapeutics (CIRC)
  • Key competitors in the antipsychotic market: Alkermes (ALKS), Otsuka Pharmaceutical (OTSK), Janssen Pharmaceuticals (JNJ)
  • Key pipeline competitors: Lundbeck (LUN), Indivior (INDV), Supernus Pharmaceuticals (SUPN)

Challenges and Opportunities:

Key Challenges:

  • Competition from established players in both existing and potential markets
  • High R&D costs and clinical trial risks
  • Dependence on the successful commercialization of pipeline drugs

Potential Opportunities:

  • Expansion into new markets with Hetlioz
  • Approval and launch of Caplyta
  • Development of novel and innovative treatments for CNS disorders

Recent Acquisitions:

  • No major acquisitions have been made by Vanda Pharmaceuticals Inc. in the past three years.

AI-Based Fundamental Rating:

Rating: 7.5/10

Justification:

  • Strong market position in N24SWD market with Hetlioz
  • Potential blockbuster status for Caplyta if approved
  • Improving financial performance
  • Robust pipeline of promising CNS treatments
  • High R&D costs and competition pose risks

Sources:

  • Vanda Pharmaceuticals Inc. Investor Relations website
  • Securities and Exchange Commission (SEC) filings
  • Market research reports from sources like Statista and EvaluatePharma

Disclaimer:

This analysis is provided for informational purposes only and should not be construed as investment advice. Investors should conduct their own research and due diligence before making any investment decisions.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters Washington, DC, United States
IPO Launch date 2006-04-12
Founder, President, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 203
Full time employees 203

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​